AngioDynamics (ANGO) News Today

AngioDynamics, Inc. (NASDAQ:ANGO) shares have been buoyed by a series of upbeat earnings reports, analyst upgrades and raised guidance, though the company remains unprofitable and has issued negative EPS outlook for FY 2026. Recent highlights include a Q1 beat on both top and bottom lines, margin expansion, stronger MedTech growth and positive cash‐flow expectations, offset by continued net losses and sub‐par long‐term profitability.

• Positive Sentiment: AngioDynamics beat Q1 EPS (-$0.10 vs. ‑$0.12 estimate) and delivered 12.1% revenue growth to $75.7 M, saw higher gross margins and raised its FY 2026 sales outlook and cash‐flow guidance. Quarterly Earnings Results
• Positive Sentiment: Zacks reports ANGO stock jumped after its Q1 loss topped consensus estimates (-$0.10 vs. ‑$0.14) on stronger revenue, while gross margin improvements supported the beat. Zacks Earnings Beat
• Positive Sentiment: Canaccord raised its price target to $18 from $17, citing stronger guidance and continued momentum. Price Target Raised
• Positive Sentiment: Benzinga notes ANGO raised its FY 2026 guidance and expects to turn positive cash flow even in the face of new tariffs. Growth Despite Tariffs
• Positive Sentiment: Seeking Alpha highlights AngioDynamics’ MedTech division driving 26.1% growth, improving margins (55.3%), controlled operating costs and a discount valuation versus peers. Discounted Sales Multiple
• Neutral Sentiment: ANGO updated its FY 2026 guidance to EPS of -$0.33–-$0.23 (vs. ‑$0.31 consensus) and revenue of $308 M–$313 M (vs. $306.9 M consensus). FY2026 Guidance
• Neutral Sentiment: A full transcript and highlights from the Q1 2026 earnings call were published, outlining strategy, product performance and tariff impacts. Earnings Call Transcript
• Neutral Sentiment: Yahoo Finance notes ANGO’s net loss widened, but analysts forecast 62% EPS growth in FY 2027, challenging bearish narratives. Losses Worsen Article
• Neutral Sentiment: Various market recaps mention AngioDynamics as a stock to watch amid mixed trading and sector momentum. Stocks to Watch
• Negative Sentiment: A Motley Fool write-up points out AngioDynamics has yet to earn an annual profit, remaining unprofitable 37 years after its founding. Profitability Concerns